RxDoctor Payments Data

Jose Santana, MD

Cardiovascular Disease · Guttenberg, NJNPI 1497750848

Payments from drug & device makers

$21,117in general payments, 2019–2025

Across 846 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$5K
  • Abbott$3K
  • Medtronic$2K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Boston Scientific$1K
  • plus $6K from 31 others

What the payments were for

  • Food & beverage$21,117100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,117 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$171,460
Medicare patients
872
Services billed
2,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban492$501,778
EntrestoSacubitril/Valsartan178$201,810
XareltoRivaroxaban179$156,742
JardianceEmpagliflozin95$104,890
VascepaIcosapent Ethyl109$57,911
Repatha SureclickEvolocumab58$34,990
EdarbyclorAzilsartan Med/Chlorthalidone74$28,630
Ranolazine ErRanolazine249$21,854
FarxigaDapagliflozin Propanediol12$20,610
OzempicSemaglutide19$18,511
Metoprolol Succinate1,229$17,268
MounjaroTirzepatide14$14,723
Praluent PenAlirocumab16$12,665
Olmesartan Medoxomil284$10,033
BrilintaTicagrelor12$9,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$467$501,778492 claims
NovartisEntresto$1,281$201,810178 claims
Johnson & JohnsonXarelto$2,384$156,742179 claims
Boehringer IngelheimJardiance$4,513$104,89095 claims
AstraZenecaFarxiga, Brilinta$218$30,57824 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$45$28,63074 claims
Novo NordiskOzempic$294$18,51119 claims
Lilly USA, LLCMounjaro$14$14,72314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Guttenberg

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →